On July 30, Alnylam Pharmaceuticals declined 20.29% in regular trading, trading at $219.64/share, with turnover of $189 million. The sharp selloff was triggered by the company's Q2 earnings report revealing a revenue miss alongside a downward revision to full-year guidance.

Alnylam reported Q2 adjusted EPS of $1.84, up significantly from $0.28 a year earlier, beating some analyst estimates. However, revenue of $1.291 billion fell short of the consensus expectation of approximately $1.32 billion, despite representing a 67% year-over-year increase from $773.7 million. Critically, the company lowered its full-year net product revenue guidance to $4.70 billion-$5.10 billion, down from the prior range of $4.90 billion-$5.30 billion.

The guidance cut validated concerns previously raised by BofA Securities regarding competitive pressure on key product Amvuttra, with long-term net price erosion expected through 2031. BofA had already trimmed its price target to $410 from $460 ahead of earnings. The combination of a top-line miss and reduced outlook intensified selling pressure across an already cautious investor base.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)